MALVERN, Pa., March 24, 2016 (GLOBE NEWSWIRE) — Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of serious acute pain, today reported financial results for the year ended December 31, 2015. “The favorable tolerability and statistically significant efficacy observed in our completed Phase II clinical trial with IV meloxicam in bunionectomy surgery patients is encouraging and the pivotal Phase III program is now underway,” said Gerri Henwood, Recro Pharma’s President and Chief Executive Officer. “We look forward to top-line data from both Phase III trials by year end 2016.  If positive, […]